Loading...

Versartis

DB:VE1
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VE1
DB
$44M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. The last earnings update was 68 days ago. More info.


Add to Portfolio Compare Print Invest
  • Versartis has significant price volatility in the past 3 months.
VE1 Share Price and Events
Price Volatility
VE1
Industry
5yr Volatility vs Market
Related Companies

VE1 Value

 Is Versartis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Versartis. This is due to cash flow or dividend data being unavailable. The share price is €1.07.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Versartis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Versartis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:VE1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in USD $-1.05
NasdaqGS:VSAR Share Price ** NasdaqGS (2018-10-12) in USD $1.21
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 31.17x
Germany Market PE Ratio Median Figure of 407 Publicly-Listed Companies 18.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Versartis.

DB:VE1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:VSAR Share Price ÷ EPS (both in USD)

= 1.21 ÷ -1.05

-1.15x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Versartis is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Versartis is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Versartis's expected growth come at a high price?
Raw Data
DB:VE1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.15x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 16 Publicly-Listed Biotechs Companies 1.61x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Versartis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Versartis's assets?
Raw Data
DB:VE1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in USD $1.90
NasdaqGS:VSAR Share Price * NasdaqGS (2018-10-12) in USD $1.21
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.43x
Germany Market PB Ratio Median Figure of 547 Publicly-Listed Companies 1.86x
DB:VE1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:VSAR Share Price ÷ Book Value per Share (both in USD)

= 1.21 ÷ 1.90

0.64x

* Primary Listing of Versartis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Versartis is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Versartis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Versartis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

VE1 Future Performance

 How is Versartis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Versartis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
50.8%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Versartis expected to grow at an attractive rate?
  • Unable to compare Versartis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Versartis's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Versartis's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:VE1 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 50.8%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:VE1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:VE1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:VE1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-06-30 40 -75 -37
2018-03-31 40 -90 -64
2017-12-31 40 -116 -85
2017-09-30 -98 -138
2017-06-30 -53 -116
2017-03-31 -54 -101
2016-12-31 -41 -96
2016-09-30 -38 -94
2016-06-30 -78 -87
2016-03-31 -70 -84
2015-12-31 -69 -82
2015-09-30 -64 -78

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Versartis is high growth as no earnings estimate data is available.
  • Unable to determine if Versartis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:VE1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Versartis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VE1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:VE1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-06-30 -1.05
2018-03-31 -1.81
2017-12-31 -2.41
2017-09-30 -3.94
2017-06-30 -3.45
2017-03-31 -3.15
2016-12-31 -3.11
2016-09-30 -3.18
2016-06-30 -2.83
2016-03-31 -2.87
2015-12-31 -2.84
2015-09-30 -2.81

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Versartis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Versartis's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Versartis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Versartis's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Versartis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Versartis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

VE1 Past Performance

  How has Versartis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Versartis's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Versartis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Versartis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Versartis's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Versartis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Versartis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VE1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 40.00 -37.49 24.86 48.33
2018-03-31 40.00 -64.24 26.43 73.51
2017-12-31 40.00 -84.98 29.17 91.91
2017-09-30 -138.24 28.06 110.03
2017-06-30 -115.79 27.74 88.02
2017-03-31 -101.31 26.08 75.80
2016-12-31 -95.82 24.34 71.98
2016-09-30 -93.81 20.80 70.84
2016-06-30 -86.85 21.57 65.57
2016-03-31 -84.40 20.82 61.12
2015-12-31 -82.18 20.08 60.03
2015-09-30 -77.71 22.20 56.04
2015-06-30 -71.16 18.25 51.16
2015-03-31 -60.09 15.97 44.84
2014-12-31 -83.07 13.51 32.61
2014-09-30 -73.23 11.57 24.46
2014-06-30 -64.41 8.68 18.52
2014-03-31 -59.46 6.46 16.23
2013-12-31 -18.50 4.43 14.86
2013-09-30 -16.58 2.56 14.37
2012-12-31 -13.22 1.94 10.96
2011-12-31 -7.17 1.78 6.37

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Versartis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Versartis has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Versartis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Versartis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Versartis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

VE1 Health

 How is Versartis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Versartis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Versartis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Versartis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Versartis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Versartis has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Versartis Company Filings, last reported 3 months ago.

DB:VE1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 68.94 0.00 67.78
2018-03-31 76.63 0.00 74.69
2017-12-31 82.76 0.00 81.15
2017-09-30 49.24 0.00 118.78
2017-06-30 95.02 0.00 143.36
2017-03-31 126.50 0.00 165.08
2016-12-31 151.07 0.00 201.15
2016-09-30 111.00 0.00 160.43
2016-06-30 135.74 0.00 137.50
2016-03-31 154.70 0.00 160.93
2015-12-31 176.50 0.00 182.07
2015-09-30 194.18 0.00 198.01
2015-06-30 212.25 0.00 214.67
2015-03-31 227.58 0.00 230.26
2014-12-31 167.37 0.00 170.57
2014-09-30 181.23 0.00 181.58
2014-06-30 193.47 0.00 192.77
2014-03-31 201.10 0.00 204.92
2013-12-31 10.70 0.00 13.29
2013-09-30 6.71 0.00 8.08
2012-12-31 -4.66 4.46 0.33
2011-12-31 1.40 0.00 0.88
  • Versartis has no debt.
  • Versartis has no debt compared to 5 years ago when it was 50.9%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Versartis has sufficient cash runway for 1.1 years based on current financial obligations.
  • Versartis has sufficient cash runway for 1.1 years if financial obligations continue to grow at historical rates of 31.4% each year.
X
Financial health checks
We assess Versartis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Versartis has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

VE1 Dividends

 What is Versartis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Versartis dividends.
If you bought €2,000 of Versartis shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Versartis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Versartis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:VE1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 322 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:VE1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Versartis has not reported any payouts.
  • Unable to verify if Versartis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Versartis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Versartis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Versartis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Versartis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Versartis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

VE1 Management

 What is the CEO of Versartis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jay Shepard, image provided by Google.
Jay Shepard
COMPENSATION $4,070,797
AGE 60
TENURE AS CEO 3.4 years
CEO Bio

Mr. Jay P. Shepard serves as Director of Esperion Therapeutics, Inc. since May 29, 2018. He has been the President and Chief Executive Officer at Versartis, Inc. since May 6, 2015. Mr. Shepard has been Principal Financial Officer of Versartis, Inc. since December 1, 2017. He served as an Executive Partner of Sofinnova Ventures, Inc. He served as the Chairman and Chief Executive Officer of NextWave Pharmaceuticals, Inc. from January 1, 2010 to November 2012 and its President until November 2012. He was employed at InterMune Inc. He originally joined Sofinnova in 2008 as an Executive in Residence and was its Venture Partner. Mr. Shepard served as an Executive in Residence at Sofinnova Ventures, Inc. since 2008 and also served as its Venture Partner. He served as the Chief Executive Officer and President of Relypsa, Inc., where he also worked as Interim President. He served as the Chief Executive Officer and Co-President of Ilypsa, Inc., and joined in December 2005. He served as Vice President of Commercial Operations of Telik Inc., since August 2002. Prior to joining Telik Inc., from 1994 to 2002, he held positions of increasing responsibility with Alza Pharmaceuticals, Inc. He served as Vice President of Oncology Business Unit at ALZA Pharmaceuticals Oncology Business Unit, having held leadership positions in its specialty pharmaceutical sales and marketing group. He was responsible for a product line that included Doxil®. Prior to 1994, he held product and sales management positions with Syntex Laboratories and Ortho Pharmaceutical Corporation. He served as an Executive Chairman of Versartis, Inc. since December 2013 until May 6, 2015 and has been its Director since December 2013. He has been an Independent Director of Sorbent Therapeutics, Inc. since June 18, 2014. He served as an Independent Director of Marinus Pharmaceuticals, Inc. since November 2013 until May 11, 2017. He served as a Director of DURECT Corporation from September 26, 2013 to August 16, 2016. He served as a Director at Bullet Biotechnology, Inc. He served as a Director of Relypsa, Inc. until September 2010. He served as an Executive Director of NextWave Pharmaceuticals, Inc. and Ilypsa, Inc. He has more than 33 years’ experience in the pharmaceutical, biotechnology and drug delivery arenas. Mr. Shepard has previously served as President and CEO of Ilypsa (acquired by Amgen), interim President and CEO of Relypsa (Ilypsa’s spin-out company, which was acquired by Galencia). Mr. Shepard is a board member of Christopher & Dana Reeve Foundation, and the Santa Clara University Entrepreneurial School. Mr. Shepard holds a Bachelor of Science Degree in Business Administration from the University of Arizona, Tucson.

CEO Compensation
  • Jay's compensation has increased whilst company is loss making.
  • Jay's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Versartis management team in years:

2.3
Average Tenure
53
Average Age
  • The tenure for the Versartis management team is about average.
Management Team

Jay Shepard

TITLE
President
COMPENSATION
$4M
AGE
60
TENURE
3.4 yrs

Tracy Woody

TITLE
Chief Commercial Officer
COMPENSATION
$3M
AGE
48
TENURE
1.6 yrs

Jeff Cleland

TITLE
Co-Founder
COMPENSATION
$670K
AGE
53

Josh Silverman

TITLE
Co-Founder
TENURE
10.8 yrs

Kevin Haas

TITLE
Vice President of Finance
AGE
53

Paul Westberg

TITLE
Senior VP & Chief Business Officer
COMPENSATION
$3M
AGE
50
TENURE
1.8 yrs

Mike Burdick

TITLE
Senior Vice President of Regulatory Affairs
TENURE
2.9 yrs

Jay Stout

TITLE
Senior Vice President of Technical Operations
AGE
56
TENURE
1.5 yrs

Kenneth Guernsey

TITLE
Secretary

George Bright

TITLE
Vice President of Clinical Development
AGE
70
Board of Directors Tenure

Average tenure and age of the Versartis board of directors in years:

7.7
Average Tenure
58
Average Age
  • The tenure for the Versartis board of directors is about average.
Board of Directors

Srini Akkaraju

TITLE
Chairman of the Board
COMPENSATION
$282K
AGE
50
TENURE
3.4 yrs

Jay Shepard

TITLE
President
COMPENSATION
$4M
AGE
60
TENURE
4.8 yrs

Mohammed Shahzad Malik

TITLE
Director
COMPENSATION
$202K
AGE
51
TENURE
7.7 yrs

John Varian

TITLE
Director
COMPENSATION
$198K
AGE
58
TENURE
4.6 yrs

Beverly Biller

TITLE
Clinical Advisor

Paul Saenger

TITLE
Clinical Advisor

Ron Rosenfeld

TITLE
Clinical Advisor

Paul Czernichow

TITLE
Clinical Advisor
TENURE
8.3 yrs

Barry Bercu

TITLE
Clinical Advisor
TENURE
8.3 yrs

Pinchas Cohen

TITLE
Clinical Advisor
AGE
61
TENURE
8.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Value (USD)
19. Jun 18 Sell Kevin Haas Individual 15. Jun 18 15. Jun 18 -143 $-328.90
19. Jun 18 Sell Paul Westberg Individual 15. Jun 18 15. Jun 18 -612 $-1,407.60
16. Jun 18 Buy Samsara BioCapital Company 13. Jun 18 13. Jun 18 53,018 $112,928.34
08. Jun 18 Buy Samsara BioCapital Company 06. Jun 18 08. Jun 18 1,055,485 $1,914,709.34
23. May 18 Sell Jay Shepard Individual 22. May 18 22. May 18 -9,232 $-13,848.00
25. Apr 18 Sell Jay Stout Individual 24. Apr 18 24. Apr 18 -4,854 $-7,523.70
26. Mar 18 Sell Tracy Woody Individual 23. Mar 18 23. Mar 18 -4,345 $-7,603.75
12. Feb 18 Sell Paul Westberg Individual 08. Feb 18 08. Feb 18 -5,355 $-9,639.00
12. Feb 18 Sell Jay Shepard Individual 08. Feb 18 08. Feb 18 -14,446 $-26,002.80
12. Feb 18 Sell Shane Ward Individual 08. Feb 18 08. Feb 18 -4,118 $-7,412.40
12. Feb 18 Sell Kevin Haas Individual 08. Feb 18 08. Feb 18 -1,599 $-2,878.20
06. Dec 17 Buy Samsara BioCapital Company 01. Dec 17 05. Dec 17 976,467 $2,115,408.12
23. Oct 17 Sell Joshua Brumm Individual 19. Oct 17 19. Oct 17 -1,326 $-3,381.30
23. Oct 17 Sell Paul Westberg Individual 19. Oct 17 19. Oct 17 -1,326 $-3,381.30
23. Oct 17 Sell Shane Ward Individual 19. Oct 17 19. Oct 17 -776 $-1,978.80
23. Oct 17 Sell Colin Hislop Individual 19. Oct 17 19. Oct 17 -667 $-1,700.85
X
Management checks
We assess Versartis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Versartis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

VE1 News

External News
Loading...
Simply Wall St News

VE1 Company Info

Map
Description

Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.

Details
Name: Versartis, Inc.
VE1
Exchange: DB
Founded: 2008
$37,948,841
36,240,673
Website: http://www.versartis.com
Address: Versartis, Inc.
1020 Marsh Road,
Menlo Park,
California, 94025,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS VSAR Common Stock Nasdaq Global Select US USD 21. Mar 2014
DB VE1 Common Stock Deutsche Boerse AG DE EUR 21. Mar 2014
Number of employees
Current staff
Staff numbers
10
Versartis employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/10/15 18:39
End of day share price update: 2018/10/12 00:00
Last estimates confirmation: 2018/03/06
Last earnings filing: 2018/08/08
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.